Teriflunomide promotes oligodendroglial differentiation and myelination

Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro

(2018) Liyang Jiang et al.   TOXICOLOGY LETTERS

Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

(2017) Diego Cadavid et al.   LANCET NEUROLOGY

Regenerating CNS myelin — from mechanisms to experimental medicines

(2017) Robin J. M. Franklin et al.   NATURE REVIEWS NEUROSCIENCE

p53-Mediated oligodendrocyte apoptosis initiates demyelination after compressed spinal cord injury by enhancing ER-mitochondria interaction and E2F1 expression

(2017) Lan Ma et al.   NEUROSCIENCE LETTERS

Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience

(2017) Aaron E. Miller   Therapeutic Advances in Neurological Disorders

Unveiling some FDA-approved drugs as inhibitors of the store-operated Ca2+ entry pathway

(2017) Saifur Rahman et al.   Scientific Reports

SomethiNG 2 talk about—Transcriptional regulation in embryonic and adult oligodendrocyte precursors

(2016) Melanie Küspert et al.   BRAIN RESEARCH

In vitro evaluation of physiologically relevant concentrations of teriflunomide on activation and proliferation of primary rodent microglia

(2016) Tanja Wostradowski et al.   Journal of Neuroinflammation

Pushing Forward: Remyelination as the New Frontier in CNS Diseases

(2016) David Kremer et al.   TRENDS IN NEUROSCIENCES

Oligodendroglial Maturation Is Dependent on Intracellular Protein Shuttling

(2015) P. Gottle et al.   JOURNAL OF NEUROSCIENCE

Genetic evidence that Nkx2.2 and Pdgfra are major determinants of the timing of oligodendrocyte differentiation in the developing CNS

(2014) Q. Zhu et al.   DEVELOPMENT

Teriflunomide (Aubagio®) for the treatment of multiple sclerosis

(2014) Amit Bar-Or   EXPERIMENTAL NEUROLOGY

Ceramide galactosyltransferase expression is regulated positively by Nkx2.2 and negatively by OLIG2

(2014) Kyohei Okahara et al.   GLYCOBIOLOGY

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Christian Confavreux et al.   LANCET NEUROLOGY

Ascl1/Mash1 Promotes Brain Oligodendrogenesis during Myelination and Remyelination

(2013) H. Nakatani et al.   JOURNAL OF NEUROSCIENCE

MYRF Is a Membrane-Associated Transcription Factor That Autoproteolytically Cleaves to Directly Activate Myelin Genes

(2013) Helena Bujalka et al.   PLOS BIOLOGY

Neuron-oligodendrocyte myelination co-culture derived from embryonic rat spinal cord and cerebral cortex

(2013) Yi Pang et al.   Brain and Behavior

Neuroprotection and repair in multiple sclerosis

(2012) Robin J. M. Franklin et al.   Nature Reviews Neurology

Evidence supporting a role for dihydroorotate dehydrogenase, bioenergetics, and p53 in selective teriflunomide-induced apoptosis in transformed versus normal human keratinocytes

(2011) Numsen Hail et al.   APOPTOSIS

Immune mechanisms of new therapeutic strategies in MS — Teriflunomide

(2011) Malte C. Claussen et al.   CLINICAL IMMUNOLOGY

Modulation of Canonical Transient Receptor Potential Channel 1 in the Proliferation of Oligodendrocyte Precursor Cells by the Golli Products of the Myelin Basic Protein Gene

(2011) P. M. Paez et al.   JOURNAL OF NEUROSCIENCE

Activation of CXCR7 receptor promotes oligodendroglial cell maturation

(2010) Peter Göttle et al.   ANNALS OF NEUROLOGY

p53-family proteins and their regulators: hubs and spokes in tumor suppression

(2010) L Collavin et al.   CELL DEATH AND DIFFERENTIATION

Regulation of Store-Operated and Voltage-Operated Ca2+ Channels in the Proliferation and Death of Oligodendrocyte Precursor Cells by Golli Proteins

(2009) Pablo M Paez et al.   ASN Neuro

p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation

(2009) D. Kremer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ascl1 is required for oligodendrocyte development in the spinal cord

(2008) M. Sugimori et al.   DEVELOPMENT